texas oncology more breakthroughs. more victories
Request an Appointment

East Texas Clinical Trials

Texas Oncology cancer centers in east Texas participate in a wide range of clinical trials and ground-breaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the east Texas area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current trials.

Our cancer researchers in the east Texas area are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks of Participating in a Clinical Trial

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the east Texas area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Clinical Trial Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the east Texas area and talk to you doctor to determine which clinical trial is right for you.

Biliary Cancer

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Longview

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01) View

Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01) View

Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)

Indication: Biliary Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01) View

Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)

Indication: Biliary Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01) View

Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01) View

Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: III

Breast Cancer

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study) View

Description: Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study) View

Description: Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study) View

Description: Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I

Colon Cancer

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Endometrial Cancer

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: III

Esophageal Cancer

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: I

Fallopian Tube Cancer

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: I

Gastric Cancer

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: I

Head and Neck Cancer

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: II

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: III

Leukemia

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Longview

Phase: II

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Paris

Phase: II

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: II

Lung Cancer

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IIIB

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: IIIB

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: IIIB

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: IIIB

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IIIB

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1/2 of Quarat Ozeplasmid and Atezolizumab with SCLC (ES-SCLC) (Acclaim-3) View

Description: A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ONC-005)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph3 study of I-Dxd in subjects with relapsed SCLC View

Description: A PHASE 3 MULTICENTER RANDOMIZED OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd) A B7-H3 ANTIBODY DRUG CONJUGATE (ADC) VERSUS TREATMENT OF PHYSICIAN'S CHOICE (TPC) IN SUBJECTS WITH RELAPSED SMALL CELL LUNG CANCER (SCLC) (IDeate-Lung02) (DS7300-188)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 study of I-Dxd in subjects with relapsed SCLC View

Description: A PHASE 3 MULTICENTER RANDOMIZED OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd) A B7-H3 ANTIBODY DRUG CONJUGATE (ADC) VERSUS TREATMENT OF PHYSICIAN'S CHOICE (TPC) IN SUBJECTS WITH RELAPSED SMALL CELL LUNG CANCER (SCLC) (IDeate-Lung02) (DS7300-188)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 study of I-Dxd in subjects with relapsed SCLC View

Description: A PHASE 3 MULTICENTER RANDOMIZED OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd) A B7-H3 ANTIBODY DRUG CONJUGATE (ADC) VERSUS TREATMENT OF PHYSICIAN'S CHOICE (TPC) IN SUBJECTS WITH RELAPSED SMALL CELL LUNG CANCER (SCLC) (IDeate-Lung02) (DS7300-188)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Lymphomas

Title: A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: II/III

Title: A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II/III

Title: OPEN-LABEL, PHASE 1 STUDY OF CD19 t-haNK AS A SINGLE AGENT AND IN COMBINATION WITH AN IL-15 SUPERAGONIST (N-803) AND RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: I

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Melanoma

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: III

Myelofibrosis

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS (SENTRY)

Indication: Myelofibrosis

Location: Texas Oncology-Tyler

Phase: I/III

Title: An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Patients With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Tyler

Phase: I

Myelomas

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: 64007957MMY2010/MM165: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

Indication: Myelomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: 64007957MMY2010/MM165: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

Indication: Myelomas

Location: Texas Oncology-Longview

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: 64007957MMY2010/MM165: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

Indication: Myelomas

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: 64007957MMY2010/MM165: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

Indication: Myelomas

Location: Texas Oncology-Paris

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: 64007957MMY2010/MM165: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1 study of ABBV-383 in subjects with relapsed or refractory MM View

Description: A Multicenter Phase 1b Open-label Study to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects with Relapsed or Refractory Multiple Myeloma (M24-108)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: I

Ovarian Cancer

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I

Pancreatic Cancer

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Pancreatic Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Pancreatic Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: I

Peritoneal Cancer

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: I

Rectal Cancer

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Rectal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Rectal Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Rectal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Rectal Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Solid Tumors

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: IV

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Texas Oncology-Longview

Title: A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: II/III

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: IIIB

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Longview

Phase: II

Title: Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01) View

Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)

Indication: Biliary Cancer

Location: Texas Oncology-Longview

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study) View

Description: Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview

Phase: I

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview

Phase: II

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Longview

Phase: III

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Longview

Phase: II

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: II

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph3 study of I-Dxd in subjects with relapsed SCLC View

Description: A PHASE 3 MULTICENTER RANDOMIZED OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd) A B7-H3 ANTIBODY DRUG CONJUGATE (ADC) VERSUS TREATMENT OF PHYSICIAN'S CHOICE (TPC) IN SUBJECTS WITH RELAPSED SMALL CELL LUNG CANCER (SCLC) (IDeate-Lung02) (DS7300-188)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: II

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: I

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Longview

Phase: III

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: 64007957MMY2010/MM165: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

Indication: Myelomas

Location: Texas Oncology-Longview

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview

Phase: I

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview

Phase: II

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Rectal Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: IV

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I

Texas Oncology-Longview Cancer Center

Title: A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IIIB

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01) View

Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study) View

Description: Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph3 study of I-Dxd in subjects with relapsed SCLC View

Description: A PHASE 3 MULTICENTER RANDOMIZED OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd) A B7-H3 ANTIBODY DRUG CONJUGATE (ADC) VERSUS TREATMENT OF PHYSICIAN'S CHOICE (TPC) IN SUBJECTS WITH RELAPSED SMALL CELL LUNG CANCER (SCLC) (IDeate-Lung02) (DS7300-188)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: 64007957MMY2010/MM165: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

Indication: Myelomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Rectal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I

Texas Oncology-Palestine Cancer Center

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IIIB

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01) View

Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)

Indication: Biliary Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: 64007957MMY2010/MM165: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

Indication: Myelomas

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Pancreatic Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Rectal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Texas Oncology-Paris

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: IIIB

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: II

Title: Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01) View

Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Paris

Phase: I

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Paris

Phase: II

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Paris

Phase: III

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Paris

Phase: II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: 64007957MMY2010/MM165: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

Indication: Myelomas

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Pancreatic Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Paris

Phase: I

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Paris

Phase: II

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Rectal Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: IV

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Texas Oncology-Tyler

Title: A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II/III

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS (SENTRY)

Indication: Myelofibrosis

Location: Texas Oncology-Tyler

Phase: I/III

Title: An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Patients With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Tyler

Phase: I

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: IIIB

Title: OPEN-LABEL, PHASE 1 STUDY OF CD19 t-haNK AS A SINGLE AGENT AND IN COMBINATION WITH AN IL-15 SUPERAGONIST (N-803) AND RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: I

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01) View

Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study) View

Description: Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1/2 of Quarat Ozeplasmid and Atezolizumab with SCLC (ES-SCLC) (Acclaim-3) View

Description: A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ONC-005)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph3 study of I-Dxd in subjects with relapsed SCLC View

Description: A PHASE 3 MULTICENTER RANDOMIZED OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd) A B7-H3 ANTIBODY DRUG CONJUGATE (ADC) VERSUS TREATMENT OF PHYSICIAN'S CHOICE (TPC) IN SUBJECTS WITH RELAPSED SMALL CELL LUNG CANCER (SCLC) (IDeate-Lung02) (DS7300-188)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: I

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: III

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: 64007957MMY2010/MM165: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1 study of ABBV-383 in subjects with relapsed or refractory MM View

Description: A Multicenter Phase 1b Open-label Study to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects with Relapsed or Refractory Multiple Myeloma (M24-108)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: I

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

No Phase

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase I

Title: An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Patients With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Tyler

Phase: I

Title: OPEN-LABEL, PHASE 1 STUDY OF CD19 t-haNK AS A SINGLE AGENT AND IN COMBINATION WITH AN IL-15 SUPERAGONIST (N-803) AND RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 study of ABBV-383 in subjects with relapsed or refractory MM View

Description: A Multicenter Phase 1b Open-label Study to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects with Relapsed or Refractory Multiple Myeloma (M24-108)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I

Title: Ph1 FIH Study of TORL-1-23 in CLDN6+ GYN NSCLC & Solid Participants View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-1-23 IN PARTICIPANTS WITH ADVANCED CANCER (TORL123-001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Phase I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 of Quarat Ozeplasmid and Atezolizumab with SCLC (ES-SCLC) (Acclaim-3) View

Description: A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ONC-005)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Pancreatic Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Pancreatic Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Rectal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Rectal Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Rectal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Rectal Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Phase I/III

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS (SENTRY)

Indication: Myelofibrosis

Location: Texas Oncology-Tyler

Phase: I/III

Phase II

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: II

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Longview

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Longview

Phase: II

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Paris

Phase: II

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: 64007957MMY2010/MM165: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

Indication: Myelomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: 64007957MMY2010/MM165: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

Indication: Myelomas

Location: Texas Oncology-Longview

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: 64007957MMY2010/MM165: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

Indication: Myelomas

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: 64007957MMY2010/MM165: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

Indication: Myelomas

Location: Texas Oncology-Paris

Phase: II

Title: SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165) View

Description: 64007957MMY2010/MM165: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Phase II/III

Title: A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: II/III

Title: A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Phase III

Title: Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01) View

Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01) View

Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)

Indication: Biliary Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01) View

Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)

Indication: Biliary Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01) View

Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01) View

Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study) View

Description: Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study) View

Description: Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study) View

Description: Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 study of I-Dxd in subjects with relapsed SCLC View

Description: A PHASE 3 MULTICENTER RANDOMIZED OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd) A B7-H3 ANTIBODY DRUG CONJUGATE (ADC) VERSUS TREATMENT OF PHYSICIAN'S CHOICE (TPC) IN SUBJECTS WITH RELAPSED SMALL CELL LUNG CANCER (SCLC) (IDeate-Lung02) (DS7300-188)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 study of I-Dxd in subjects with relapsed SCLC View

Description: A PHASE 3 MULTICENTER RANDOMIZED OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd) A B7-H3 ANTIBODY DRUG CONJUGATE (ADC) VERSUS TREATMENT OF PHYSICIAN'S CHOICE (TPC) IN SUBJECTS WITH RELAPSED SMALL CELL LUNG CANCER (SCLC) (IDeate-Lung02) (DS7300-188)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 study of I-Dxd in subjects with relapsed SCLC View

Description: A PHASE 3 MULTICENTER RANDOMIZED OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd) A B7-H3 ANTIBODY DRUG CONJUGATE (ADC) VERSUS TREATMENT OF PHYSICIAN'S CHOICE (TPC) IN SUBJECTS WITH RELAPSED SMALL CELL LUNG CANCER (SCLC) (IDeate-Lung02) (DS7300-188)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: III

Phase IIIB

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IIIB

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: IIIB

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: IIIB

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: IIIB

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IIIB

Phase IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: IV